SABI Mind Releases Global Psychedelic Survey: The World’s Most Comprehensive Assessment of Global Psychedelic Use

May 24, 2023 [CALGARY, AB] – Building upon the success of the Canadian Psychedelic Survey (CPS), SABI Mind is proud to announce the launch of the Global Psychedelic Survey (GPS). This groundbreaking initiative aims to provide English-speaking adults from around the globe with the opportunity to participate in the most extensive assessment of global psychedelic use to date.

SABI Mind is a leading psychedelic clinic and research organization that provides psychedelic-assisted therapies in Calgary and at upcoming locations in Edmonton and Victoria.

“We firmly believe that the primary experts on psychedelic substances are the consumers themselves”, said Philippe Lucas PhD, President at SABI Mind, and Primary Investigator of GPS. “They possess invaluable knowledge that can drive evidence-based policy and research.” By sharing their lived experiences through the Global Psychedelic Survey, participants can contribute to reducing stigma and informing policy decisions that impact safe and legal access to psychedelics for both medical and non-medical use.

The Global Psychedelic Survey invites participants to provide insights into their experiences with various psychedelic substances, including psilocybin, LSD, MDMA, DMT, and others. The survey covers a range of topics, such as personal motivations, therapeutic benefits, potential risks, and broader societal implications. This multidisciplinary cross-sectional survey is co-sponsored by SABI Mind, The Multidisciplinary Association of Psychedelic Studies (MAPS), Mind Medicine Australia, and Tiny. Additionally, the survey benefits from several academic collaborations, including UCLA via co-investigator Stephanie Lake PhD, and contributions from prestigious academic institutions such as Johns Hopkins, University of Alabama, University of Michigan, Cleveland Clinic, McMaster, McGill, the University of Victoria, and UBC.

“This survey is a critical step towards generating a nuanced understanding of the benefits, risks, and patterns of psychedelic use worldwide,” said Heesoo Cho, Founder and Managing Director of SABI Mind. “We encourage everyone, regardless of background or experience, to take part in this survey.”

The insights gained from the survey will not only contribute to public education and awareness but may help shape policies that prioritize the well-being and safety of individuals who choose to engage with psychedelics. SABI Mind is committed to fostering a responsible and informed approach to psychedelic use, promoting harm reduction strategies, and facilitating evidence-based decision-making processes.

Participation is anonymous and confidential, and will take 20-30 minutes. To participate in the Global Psychedelic Survey, visit: https://study.quantifiedcitizen.com/gps2023. The survey will remain open until June 2nd.

For more information on SABI Mind and the Global Psychedelic Survey, please visit: www.sabimind.com.

About SABI Mind 

Based in Calgary, SABI Mind supports the careful and necessary mending of mental health and chronic pain through psychedelic-assisted therapies. Founded by a group of Calgary-based entrepreneurs brought face-to-face with the challenges of those suffering from mental health conditions, SABI Mind empowers those discouraged by the conventional medicine methods with a patient-centred treatment model supported by experienced psychiatrists, anesthesiologists, therapists, client experience specialists, and other clinic staff specially trained in psychedelic-assisted psychotherapy.

Learn more at www.sabimind.com. Follow SABI Mind on Instagram: www.instagram.com/sabimind/, Facebook: www.facebook.com/SABIMIND and Twitter: https://twitter.com/SabiMind